Liquidia Posts $74.7M Q2 Profit as YUTREPIA Sales Surge to $170.4M
LQDA has more than doubled off its 52-week low of $19.9.
Summary
Liquidia delivered a strong Q2 with net income of $74.7 million, its fourth straight profitable quarter, driven by YUTREPIA net product sales of $170.4 million — up from $6.5 million a year ago. The inhaled prostacyclin market has grown nearly 40% since launch, and YUTREPIA has captured an increasing share, with over 5,000 patients started on treatment and more than 1,100 prescribers. Cash rose to $284.2 million, providing ample runway. The company also began enrolling patients in the Re-Spire pivotal study for L606, its next-generation inhaled therapy. This follows a period of heavy insider selling, but the commercial momentum and pipeline progress may shift focus back to fundamentals. The earnings call at 8:30 a.m. ET today will provide further color on guidance and litigation updates.
At the time of this announcement, LQDA was trading at $90.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $19.90 to $93.61. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.